Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.46 |
| ▸ | RAB9A | P51151 | 7/20 | 0.46 |
| ▸ | GAA | P10253 | 4/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.46 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | CCR4 | P51679 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 8/20 | 0.42 |
| ▸ | MEN1 | O00255 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | CASP3 | P42574 | 2/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.42 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4713147 | 0.82 | SMN1; SMN2 (0.40) | KMT2ARAB9AGAAMAPTMEN1 | |
| SCHEMBL20578862 | 0.81 | NPC1 (0.51) | KMT2ARAB9AGAAHSD17B10MAPT | |
| SCHEMBL27929163 | 0.81 | MEN1 (0.49) | KMT2ARAB9AGAAMAPTMEN1 | |
| SCHEMBL20578808 | 0.81 | MAPT (0.47) | KMT2ARAB9AMAPTMEN1ALDH1A1 | |
| SCHEMBL5692832 | 0.69 | CA1 (0.48) | KMT2AGAAMEN1ALDH1A1TSHR | |
| SCHEMBL11666704 | 0.67 | RAB9A (0.59) | KMT2ARAB9AGAACSNK2A1PLK3 | |
| SCHEMBL1819182 | 0.65 | MAPT (0.59) | KMT2ARAB9AGAACSNK2A1PLK3 | |
| SCHEMBL722560 | 0.65 | RAB9A (0.59) | KMT2ARAB9AGAACSNK2A1PLK3 | |
| SCHEMBL8625316 | 0.64 | HSD17B10 (0.42) | KMT2ARAB9AGAACSNK2A1PLK3 | |
| Bromide SCHEMBL7502411 | 0.64 | RAB9A (0.57) | KMT2ARAB9AGAACSNK2A1PLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112512522-A | Compounds for the treatment of triple negative breast and ovarian cancer | 田纳西大学研究基金会 | 2021-03-16 | — | — | CN | claimed |
| CN-112437664-A | Compounds for the treatment of pancreatic cancer | 田纳西大学研究基金会 | 2021-03-02 | — | — | CN | claimed |
| EP-2608671-B1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX INC (US) | 2018-12-12 | — | — | EP | claimed |
| CN-103442566-B | The compound of Therapeutic cancer | GTX, INC. (US) | 2015-12-09 | — | — | CN | claimed |
| CN-103442566-A | Compounds for treatment of cancer | GTX INC | 2013-12-11 | — | — | CN | claimed |
| EP-1351946-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2003-10-15 | — | — | EP | claimed |
| US-20020165218-A1 | Materials and methods to potentiate cancer treatment | LUITPOLD PHARMACEUTICALS, INC. | 2002-11-07 | — | — | US | claimed |
| WO-2002020500-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2002-03-14 | — | — | WO | claimed |
| CN-112512522-A | Compounds for the treatment of triple negative breast and ovarian cancer | 田纳西大学研究基金会 | 2021-03-16 | — | — | CN | disclosed |
| CN-112437664-A | Compounds for the treatment of pancreatic cancer | 田纳西大学研究基金会 | 2021-03-02 | — | — | CN | disclosed |
| CN-105585565-B | - 4- thiazole the pyridine derivative of anilino- containing 2- and its preparation method and pharmaceutical composition and purposes | 中国医学科学院药物研究所 | 2019-10-01 | — | — | CN | disclosed |
| CN-103442566-B | The compound of Therapeutic cancer | GTX, INC. (US) | 2015-12-09 | — | — | CN | disclosed |
| CN-102883607-B | Compounds for the treatment of cancer | GTX INC | 2015-07-22 | — | — | CN | disclosed |
| CN-104592205-A | COMPOUNDS FOR TREATMENT OF CANCER | GTX INC | 2015-05-06 | — | — | CN | disclosed |
| US-6177454-B1 | ANTIDIABETIC AGENTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2001-01-23 | — | — | US | disclosed |
| US-6048884-A | ANTIDIABETIC AGENTS; HYPOGLYCEMIC AGENTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2000-04-11 | — | — | US | disclosed |
| EP-0972769-A1 | NOVEL AMIDE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2000-01-19 | — | — | EP | disclosed |
| US-4735957-A | ANTIULCER AGENTS, CARDIOTONIC AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-04-05 | — | — | US | disclosed |
| US-4649146-A | ANTIULCER | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-03-10 | — | — | US | disclosed |
| EP-0117082-A2 | Thiazole derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165218-A1 | Materials and methods to potentiate cancer treatment | DCK, CHEK2, CHEK1 | KMT2A 1686/4885RAB9A 3831/4885GAA 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.